Abstract
Objective Osteoarthritis (OA) is increasingly seen as a disease of global joint dysfunction, affecting not only cartilage but also the other joint tissues. Extracellular matrix (ECM) is a critical determinant of tissue mechanobiology, but ECM is poorly understood in osteoarthritic joint tissues beyond cartilage in human OA and animal models of OA. Therefore, we aimed to define the structural composition and architecture of non-cartilage soft joint tissue ECM in human OA, and to compare the ECM changes observed in humans to those seen in animal models of OA.
Design A systematic search strategy, devised using relevant matrix, tissue, and disease nomenclature, was run through the MEDLINE, EMBASE, and Scopus databases. Demographic, clinical, and biological data were extracted from eligible studies. Bias analysis was performed.
Results 142 studies were included, which covered capsule, ligaments, meniscus, skeletal muscle, synovium, and tendon in both humans and animals, and fat pad and intervertebral disc in humans only. Overall, included studies show that the expression of structural ECM components changes in disease within an ECM that becomes disorganised with increasing joint degeneration.
Conclusions This systematic review consolidates existing knowledge of a poorly defined aspect of OA pathophysiology. Changes in ECM composition and architecture occur across soft joint tissues in OA, but most of these remain poorly defined due to the low number of studies and lack of healthy comparator groups. Further research to better understand the context within which cartilage is damaged in OA may enable a better understanding of OA and its potential treatments.
What is already known on this topic
Extracellular matrix (ECM) is a critical determinant of tissue mechanobiology and cell behaviour, but it is poorly described in osteoarthritic joint tissues beyond cartilage.
What this study adds
Our study highlights the global nature of ECM dysregulation across the osteoarthritic joint. In addition, this study describes practical and methodological challenges that should be addressed to improve the contribution of future studies to define the role of ECM in non-cartilage soft tissues in osteoarthritis.
How this study might affect research, practice or policy
A better understanding of ECM changes and their underlying mechanisms throughout the osteoarthritic joint may assist with disease classification and patient stratification and also holds promise for the development of ECM-targeting treatments which could modify the pathogenic cell behaviour that may drive osteoarthritis progression.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the National Institute for Health Research Oxford Biomedical Research Centre. JYM is funded by Versus Arthritis (22873) and was supported the Chan Zuckerberg Initiative (CZIF2019-002426). SJBS is funded by the Chan Zuckerberg Initiative (CZIF2019-002426 and CZIF2021-240342) and supported by the National Institute for Health Research Oxford Biomedical Research Centre. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data availability statement
The authors confirm that the data supporting the findings of this study are available within the article and its supplementary materials. In addition, the raw data from the data extraction process, which was used to populate Tables 1 and 2 and Supplementary Tables 1 and 2, is available upon reasonable request from the corresponding author (JYM).
